Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...

A handful of Section III student-athletes have chosen to play sports at the collegiate level. The top Central New York athletes have committed and signed on to play their sport at colleges and ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.